Specifically it will be the EMA CHMP recommendation for approval, but it will be in next month's meeting.
It is coming & will be another big catalyst up (25%+) as it represents an expanding market opportunity with still no competition.
System....just curious about EMA approval. I totally believe that EMA will approve this drug. what makes you think that it will be approved by 05/25/13? company said mid year...so may be june/july? but you have given a specific date. I would liketo know your rationale.
system is looking at his matrix, left and right
he is gay but also has a wife and family
he does both, and a very good liar, pumper
read through all my text, u will understand this POS will never get to the 5% the level mgt and sytem have pumping
dirty cheap API
Pfizer dumped a better cpd for puppy soup (100 dollar per month, cherry flovored)
competition from Amgen is coming (a better drug without liver Tox)
patient number is fake
cheap drug can be bought from mail order fro EU/Canada/OLD Mexico etc
Sentiment: Strong Sell
Just from the biopharmacatalyst website calendar. They have it listed #$%$25/2013 which is just before the next EMA CHMP meeting. While that isn't an official website, they tend to be fairly accurate with their estimates (but they are just estimates).
Search biopharmacatalyst ema calendar
And it should bring it up from any search tool.
The EU has a population of 739.2M compared with the US at 313.9M people. Therefore, if there is an estimated 3,000 patients in the U.S., if we apply the same ratio of patients to general population, then the EU should have approximately 7,064 patient candidates for Lomitapide, effectively tripling the available population to treat (from 3K to 10.064K).